Adolescents and adults
In adolescents and adults, no evidence of an additional benefit is available for the administration of formoterol/budesonide in a fixed combination inhaler compared with the administration of formoterol and budesonide in separate inhalers (or vice versa) regarding patient-relevant therapy goals. In fact, when applying the same inhaling system (Turbohaler(TM)), the trials on formoterol and budesonide provide similar results for fixed combination inhalers and separate inhalers.
In adolescents and adults, no evidence of an additional benefit is available for the administration of salmeterol/fluticasone in a fixed combination inhaler compared with the administration of salmeterol and fluticasone in separate inhalers (or vice versa) regarding patient-relevant therapy goals. In fact, when applying the same inhaling system (Diskus(TM)), the trials on salmeterol and fluticasone also provide similar results for fixed combination inhalers and separate inhalers.
In adolescents and adults, no evidence of a difference in benefit is available between the fixed combinations of formoterol/budesonide versus salmeterol/fluticasone. Overall, the trials provide similar results regarding the use of both fixed combinations (when applying Turbohaler(TM) or Diskus(TM)).
Children
Data in children were only available for the comparison between salmeterol/fluticasone administered by a fixed combination inhaler and salmeterol and fluticasone administered by separate inhalers (1 trial). This trial did not provide evidence of a difference between the two different forms of administration of salmeterol and fluticasone.
Due to the lack of data, no statement can be made on the comparison between formoterol/budesonide administered by a fixed combination inhaler versus formoterol and budesonide administered by separate inhalers in children.